Price Chart

Profile

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
URL https://www.cyclotherapeutics.com
Investor Relations URL N/A
HQ State/Province Florida
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 14, 2024 (est.)
Last Earnings Release Aug. 14, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
URL https://www.cyclotherapeutics.com
Investor Relations URL N/A
HQ State/Province Florida
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 14, 2024 (est.)
Last Earnings Release Aug. 14, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A